ATE442189T1 - Kombination von cytochrom-p450-abhängigen protease-inhibitoren - Google Patents

Kombination von cytochrom-p450-abhängigen protease-inhibitoren

Info

Publication number
ATE442189T1
ATE442189T1 AT02793018T AT02793018T ATE442189T1 AT E442189 T1 ATE442189 T1 AT E442189T1 AT 02793018 T AT02793018 T AT 02793018T AT 02793018 T AT02793018 T AT 02793018T AT E442189 T1 ATE442189 T1 AT E442189T1
Authority
AT
Austria
Prior art keywords
cytochrome
combination
protease inhibitors
dependent protease
dependent
Prior art date
Application number
AT02793018T
Other languages
English (en)
Inventor
Der Geest Ronald Van
Paul Stoffels
Cornelis Groen
Dirk Jochmans
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8181408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE442189(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Application granted granted Critical
Publication of ATE442189T1 publication Critical patent/ATE442189T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT02793018T 2001-12-12 2002-12-12 Kombination von cytochrom-p450-abhängigen protease-inhibitoren ATE442189T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01204841 2001-12-12
PCT/EP2002/014277 WO2003049746A2 (en) 2001-12-12 2002-12-12 Combination of cytochome p450 dependent protease inhibitors

Publications (1)

Publication Number Publication Date
ATE442189T1 true ATE442189T1 (de) 2009-09-15

Family

ID=8181408

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02793018T ATE442189T1 (de) 2001-12-12 2002-12-12 Kombination von cytochrom-p450-abhängigen protease-inhibitoren

Country Status (28)

Country Link
US (1) US20050119338A1 (de)
EP (1) EP1458447B1 (de)
JP (1) JP2005511723A (de)
KR (1) KR100974921B1 (de)
CN (1) CN100335060C (de)
AR (1) AR037797A1 (de)
AT (1) ATE442189T1 (de)
AU (1) AU2002358713B2 (de)
BR (1) BR0215043A (de)
CA (1) CA2469343C (de)
CY (1) CY1110604T1 (de)
DE (1) DE60233677D1 (de)
DK (1) DK1458447T3 (de)
ES (1) ES2333206T3 (de)
HK (1) HK1070008A1 (de)
HR (1) HRP20040619A2 (de)
HU (1) HUP0402644A3 (de)
IL (1) IL162353A0 (de)
MX (1) MXPA04005755A (de)
NO (1) NO20042666L (de)
NZ (1) NZ533826A (de)
PL (1) PL373072A1 (de)
PT (1) PT1458447E (de)
RU (1) RU2329050C2 (de)
SI (1) SI1458447T1 (de)
TW (1) TWI286476B (de)
WO (1) WO2003049746A2 (de)
ZA (1) ZA200404633B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE353323T1 (de) * 2003-09-30 2007-02-15 Tibotec Pharm Ltd Verfahren zur herstellung von benzoxazolsulfonamidverbindungen und zwischenprodukten davon
WO2005063209A1 (en) * 2003-12-23 2005-07-14 Tibotec Pharmaceuticals Ltd. Self-microemulsifying drug delivery systems of a hiv protease inhibitor
AU2005244121B2 (en) * 2004-05-07 2012-01-19 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
JP2008505870A (ja) * 2004-07-08 2008-02-28 テイボテク・フアーマシユーチカルズ・リミテツド 抗ｈｉｖ逆転写酵素およびプロテアーゼ阻害剤の組合せ剤
RU2421459C2 (ru) 2005-02-25 2011-06-20 Тиботек Фармасьютикалз Лтд. Синтез предшественника ингибитора протеазы
EP1865967A4 (de) * 2005-04-08 2011-02-09 Chimerix Inc Verbindungen, zusammensetzungen und verfahren zur behandlung viraler infektionen und anderer erkrankungen
AR053845A1 (es) * 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
TWI385173B (zh) * 2005-11-28 2013-02-11 Tibotec Pharm Ltd 作為ｈｉｖ蛋白酶抑制劑之經取代的胺基苯基磺醯胺化合物
TWI432438B (zh) * 2005-11-28 2014-04-01 Tibotec Pharm Ltd 作為ｈｉｖ蛋白酶抑制劑之經取代的胺基苯基磺醯胺化合物及衍生物
WO2007079260A1 (en) * 2005-12-30 2007-07-12 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
JO2841B1 (en) * 2006-06-23 2014-09-15 تيبوتيك فارماسيوتيكالز ليمتد 2-(substituted-amino) -benzothiazole sulfonamide as protease inhibitors HIV (HIV)
CN101674822A (zh) * 2006-08-18 2010-03-17 塞阔伊亚药品公司 抑制细胞色素p450的组合物和方法
EP2139883A4 (de) * 2007-03-23 2011-06-22 Univ Massachusetts Hiv-1-proteasehemmer
UA103013C2 (uk) 2007-12-06 2013-09-10 Тиботек Фармасьютикелз Амідні сполуки як активатори противірусних препаратів
GT200800303A (es) * 2007-12-24 2009-09-18 Combinacion anti-retroviral
CA2713105C (en) 2008-01-25 2016-06-07 Chimerix, Inc. Methods of treating viral infections
CN102239153B (zh) 2008-10-07 2016-05-11 爱尔兰詹森科学公司 作为抗病毒剂促进剂的酰胺化合物
US8921349B2 (en) 2009-05-11 2014-12-30 Purdue Research Foundation Compounds and methods for treating AIDS and HIV infections
JO3090B1 (ar) * 2009-12-11 2017-03-15 Janssen Sciences Ireland Uc 5- امينو-4- هيدروكسي-بنتويل اميدات
AU2011216243B2 (en) 2010-02-12 2015-07-09 Chimerix, Inc. Nucleoside phosphonate salts
EP2563367A4 (de) 2010-04-26 2013-12-04 Chimerix Inc Verfahren zur behandlung von retroviren-infektionen und entsprechende dosierungspläne
US8513291B2 (en) * 2010-06-01 2013-08-20 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
AU2012280198B2 (en) 2011-07-07 2016-12-22 Gilead Sciences, Inc. Darunavir combination formulations
SI2729128T1 (sl) 2011-07-07 2016-11-30 Janssen Sciences Ireland Uc Formulacije darunavirja

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7973994A (en) * 1993-10-13 1995-05-04 Merck & Co., Inc. Combination therapy for hiv infection
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
DE69735545T2 (de) * 1996-08-05 2006-08-10 Myriad Genetics, Inc., Salt Lake City Verwendung von beta-blatt mimetika als protease und kinase hemmer und alshemmer eines transkriptionsfaktors
US6180634B1 (en) * 1997-11-13 2001-01-30 Merck & Co., Inc. Combination therapy for the treatment of AIDS
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
WO1999067254A2 (en) * 1998-06-23 1999-12-29 The United States Of America Represented By The Secretary, Department Of Health And Human Services Multi-drug resistant retroviral protease inhibitors and use thereof
WO1999067417A2 (en) * 1998-06-23 1999-12-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Fitness assay and associated methods
CO5090830A1 (es) * 1998-07-20 2001-10-30 Abbott Lab Poliformo de un agente farmaceutico
TNSN00027A1 (fr) * 1999-02-12 2005-11-10 Vertex Pharma Inhibiteurs de l'aspartyle protease
DK1159278T3 (da) * 1999-02-12 2006-04-10 Vertex Pharma Inhibitorer af aspartylprotease

Also Published As

Publication number Publication date
NZ533826A (en) 2006-04-28
TW200409624A (en) 2004-06-16
KR20040071182A (ko) 2004-08-11
EP1458447B1 (de) 2009-09-09
IL162353A0 (en) 2005-11-20
WO2003049746A3 (en) 2003-12-31
AR037797A1 (es) 2004-12-01
HUP0402644A3 (en) 2008-04-28
CA2469343C (en) 2008-05-13
AU2002358713A1 (en) 2003-06-23
US20050119338A1 (en) 2005-06-02
HUP0402644A2 (en) 2007-02-28
RU2329050C2 (ru) 2008-07-20
SI1458447T1 (sl) 2010-01-29
MXPA04005755A (es) 2004-09-10
PT1458447E (pt) 2009-12-16
DE60233677D1 (de) 2009-10-22
CY1110604T1 (el) 2015-04-29
EP1458447A2 (de) 2004-09-22
RU2004121144A (ru) 2005-04-20
AU2002358713B2 (en) 2009-01-29
ES2333206T3 (es) 2010-02-18
HK1070008A1 (en) 2005-06-10
CN100335060C (zh) 2007-09-05
BR0215043A (pt) 2004-11-03
WO2003049746A2 (en) 2003-06-19
ZA200404633B (en) 2005-09-01
JP2005511723A (ja) 2005-04-28
KR100974921B1 (ko) 2010-08-09
NO20042666L (no) 2004-09-09
DK1458447T3 (da) 2010-01-18
HRP20040619A2 (en) 2005-08-31
PL373072A1 (en) 2005-08-08
CN1604803A (zh) 2005-04-06
TWI286476B (en) 2007-09-11
CA2469343A1 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
ATE442189T1 (de) Kombination von cytochrom-p450-abhängigen protease-inhibitoren
ATE370938T1 (de) Pro-pharmakon von cox-2-inhibitoren
CY2012007I2 (el) Πεπτιδομιμητικοι αναστολεις πρωτεασης
CY2015028I2 (el) Ενας αναστολεας ν-ακυλοσφιγγοσινο γλυκοζυλοτρανσφερασης
DE60135087D1 (de) Dipeptidnitrile als inhibitoren von cathepsin k
ATE333463T1 (de) Selektive dipeptidische inhibitoren von kallikrein
NO20034045L (no) Metallproteinase-inhibitorer
MXPA03007049A (es) Inhibidores heterociclicos de erk2 y usos de los mismos.
DK1567529T4 (da) Pseudopolymorfe former af en hiv-proteaseinhibitor
ATE397925T1 (de) Cis-imidazoline als mdm2-hemmer
DE602005019971D1 (de) Inhibitoren von cysteinprotease
NO20042719L (no) Substituerte 2-amino-cykloalkankarboksamider og deres anvendelse som protease-inhibitorer
DK1466979T3 (da) Lysyloxidaser af svampeoprindelse
ATE429431T1 (de) 2-amino-benzoxazol-suphonamide als breitspektrum- hiv-protease-inhibitoren
NO20025786L (no) Protaseinhibitorer
NO20043114L (no) Bredspektrede heterocyklisk substituerte fenylinneholdende sulfonamid-HIV-proteaseinhibitorer
NO20025005L (no) Proteaseinhibitorer
IL156776A0 (en) Inhibitors of cruzipain and other cysteine proteases
DK1453852T3 (da) Selektive arylguanidinpeptider som urokinaseinhibitorer
IL156775A0 (en) Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases
NO20032328L (no) Proteaseinhibitorer
DE60124397D1 (de) Inhibitoren von serinproteasen
AU2002350322A1 (en) Inhibitors of hepatitis c virus protease
ZA200305260B (en) Inhibitors of cruzipain and other cysteine proteases.
ZA200305259B (en) Inhibitors of cruzipain and other cysteine proteases.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1458447

Country of ref document: EP

RZN Patent revoked